NKTX ($NKTX) Insider Trading & Smart Money Activity

NKTX · Biotechnology · Latest filing Jun 18, 2026

$NKTX has 1 insider trade on file. In the last 12 months on the open market, no insider bought and 1 insider sold ($4.81K), net -$4.81K.

Insider buyers (12 mo): 0
Insider sellers (12 mo): 1
Net insider $ (12 mo): -$4.81K
Congress trades (12 mo): 0
13F moves on file: 0
Analyst ratings on file: 0

NKTX insider buying and selling by quarter

Quarter	Insider sales	Congress buys / sales	13F added / cut
Q1 2026	0	0 / 0	0 / 0
Q2 2026	1 · $4.81K	0 / 0	0 / 0
Q3 2026	0	0 / 0	0 / 0
Q4 2026	0	0 / 0	0 / 0

Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.

All NKTX insider, congress, 13F and analyst activity

Date	Source	Who	Action	Shares	Value / amount	ΔOwn	1W	1M	6M	Filing	Story
Jun 18, 2026	Insider	Paul HastingsChief Executive Officer	Sell (Open-market sale)	1.78K sh	$4.81K						—

1W / 1M / 6M = how NKTX moved from the trade or filing date.

Insider trading in NKTX: who is buying and selling

Insider	Role	Trades	Open-market net	Shares held	Last trade
Paul Hastings	Chief Executive Officer	1	-$4.81K		Jun 18, 2026

Frequently asked questions

Are NKTX insiders buying or selling?

Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 1 insider made 1 open-market sale worth $4.81K, a net -$4.81K.

What is the latest insider trade in NKTX?

Paul Hastings, Chief Executive Officer filed a sell (open-market sale) of 1.78K sh worth $4.81K on Jun 18, 2026.

Other biotechnology stocks

All stocks Insider cluster buys Top insider purchases Congress 13F institutions

Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.

Get trade alerts by text